瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06938 瑞博生物-B

休市中 01-30 16:08:02

68.800

-4.200

-5.75%

最高73.000	最低67.600	成交量77.62万
今开73.000	昨收73.000	日振幅7.40%
总市值114.21亿	流通市值114.21亿	总股本1.66亿
成交额5,345万	换手率0.47%	流通股本1.66亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":68.8,"timestamp":1769760482514,"preClose":73,"halted":0,"volume":776200,"delay":0,"changeRate":-0.05753424657534251,"floatShares":166000000,"shares":166000000,"eps":-1.855,"marketStatus":"休市中","change":-4.2,"latestTime":"01-30 16:08:02","open":73,"high":73,"low":67.6,"amount":53453455,"amplitude":0.073973,"askPrice":68.8,"askSize":600,"bidPrice":68.55,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.502,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769995800000},"marketStatusCode":7,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":73,"openAndCloseTimeList":[[1769736600000,1769745600000],[1769749200000,1769760000000]],"volumeRatio":2.054091,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938","defaultTab":"news","newsList":[{"id":"2607720738","title":"瑞博生物-B01月28日遭主力抛售245.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607720738","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607720738?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:16","pubTimestamp":1769588167,"startTime":"0","endTime":"0","summary":"01月28日, 瑞博生物-B股价跌4.11%，报收73.50元，成交金额4585.4万元，换手率0.38%，振幅7.37%，量比1.96。瑞博生物-B今日主力资金净流出245.2万元，上一交易日主力净流出68.7万元。该股近5个交易日下跌4.10%，主力资金累计净流出269.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出3442.2万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128162936a6b6740b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128162936a6b6740b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2606272282","title":"华福证券：医药生物业新技术全面突破 战略看多中国创新出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2606272282","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606272282?lang=zh_cn&edition=full","pubTime":"2026-01-27 11:01","pubTimestamp":1769482871,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华福证券发布研报称，2025年中国创新药全球竞争力凸显，出海交易创新高，多家企业扭亏为盈。战略看多中国创新出海。华福证券主要观点如下：国内复盘：全球竞争力凸显，企业扭亏为盈+管线出海价值新高度2025创新药指数大涨，Biopharma和Biotech持仓比例显著提升，核心驱动因素是中国创新药全球竞争力凸显。创新药市场份额快速提升，肿瘤与免疫领域创新药份额超32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127110355a6b10694&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127110355a6b10694&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1574","09887","02157","02615","BK1161","02162","02096","06160","09926","01276","06938","01530","06978","09606","01672","BK1583","06955","01801","HK0000165453.HKD","01093"],"gpt_icon":0},{"id":"2606695240","title":"瑞博生物-B01月26日获主力加仓25.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606695240","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606695240?lang=zh_cn&edition=full","pubTime":"2026-01-26 16:15","pubTimestamp":1769415352,"startTime":"0","endTime":"0","summary":"01月26日, 瑞博生物-B股价涨0.06%，报收78.75元，成交金额1488.8万元，换手率0.11%，振幅3.49%，量比0.22。瑞博生物-B今日主力资金净流入25.9万元，上一交易日主力净流入19.8万元。该股近5个交易日上涨4.87%，主力资金累计净流入455.7万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流出3128.3万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126162259a6ad635b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126162259a6ad635b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2605458044","title":"瑞博生物-B(06938)：RBD5044于中国的II期临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2605458044","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605458044?lang=zh_cn&edition=full","pubTime":"2026-01-23 07:14","pubTimestamp":1769123663,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，本集团自主研发的RBD5044注射液已获中国国家药品监督管理局的II期临床试验默示许可。RBD5044是一款靶向APOC3的siRNA药物。APOC3是一种几乎只在肝脏中合成的蛋白质，在脂质代谢中起关键作用。RBD5044可以解决与高甘油三酯血症相关的并发症，成为管理血脂紊乱的一种治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B(06938)：RBD5044于中国的II期临床试验默示许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2605408430","title":"十年投资布局“结果”！这家山西医药龙头参股企业赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2605408430","media":"晋融社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605408430?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:17","pubTimestamp":1769005020,"startTime":"0","endTime":"0","summary":"近日，苏州瑞博生物技术股份有限公司在港交所正上市。据了解，仟源医药旗下基金持有瑞博生物2.64%股权。事实上，仟源医药近年来频繁进行投资布局，通过参股、并购多家子公司，实现了业务扩展。在创新药方面，2024年3月，仟源医药与北京亿药科技共同成立合资公司“仟源亿药”，仟源医药出资7200万元并持有60%股权。2025年第三季度报告显示，公司对联营企业的投资收益为146.94万元，较上年同期增长61.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121224152953dc297&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121224152953dc297&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","06938","BK1574","09939","BK1161"],"gpt_icon":0},{"id":"2605110061","title":"瑞博生物-B01月20日主力净流入421.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2605110061","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605110061?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:15","pubTimestamp":1768896931,"startTime":"0","endTime":"0","summary":"01月20日，瑞博生物-B股价收平报75.00元，成交金额1.0亿元，换手率0.83%，振幅6.60%，量比1.14。瑞博生物-B今日主力资金净流入421.2万元，上一交易日主力净流出1227.8万元。该股近5个交易日下跌7.29%，主力资金累计净流出3122.0万元；近20日主力资金累计净流出3162.9万元，其中净流出天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120162426a72fb2d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120162426a72fb2d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2603720856","title":"瑞博生物-B01月15日遭主力抛售775.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603720856","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603720856?lang=zh_cn&edition=full","pubTime":"2026-01-15 16:15","pubTimestamp":1768464929,"startTime":"0","endTime":"0","summary":"01月15日, 瑞博生物-B股价跌0.13%，报收76.05元，成交金额8580.1万元，换手率0.67%，振幅9.85%，量比0.00。瑞博生物-B今日主力资金净流出775.0万元，连续3日净流出，上一交易日主力净流出360.7万元。该股近5个交易日上涨30.07%，主力资金累计净流出1176.6万元；近20日主力资金累计净流出1176.6万元，其中净流出天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115161814a71dade3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115161814a71dade3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938"],"gpt_icon":1},{"id":"2603627052","title":"港股异动 | 瑞博生物-B(06938)午前涨超3% 公司管线具备FIC潜力 已经率先进入2期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2603627052","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603627052?lang=zh_cn&edition=full","pubTime":"2026-01-15 11:54","pubTimestamp":1768449256,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞博生物-B午前涨超3%，截至发稿，涨2.63%，报78.15港元，成交额4831.37万港元。根据招股书披露，瑞博生物目前有六款自研siRNA药物处于临床试验阶段，涉及七种适应症，其中四款进入2期临床试验；另有超过20个临床前资产持续推进中。竞争格局方面，公司管线具备FIC潜力，已经率先进入2期临床，目前处于治疗冠状动脉疾病的2a期临床试验中，公司预计将在年内开展2b期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393173.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938"],"gpt_icon":1},{"id":"2603942046","title":"2026开年，创新药迎来暖风","url":"https://stock-news.laohu8.com/highlight/detail?id=2603942046","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603942046?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:39","pubTimestamp":1768383558,"startTime":"0","endTime":"0","summary":"2026年开年以来，创新药板块的情绪明显回暖。进入2026年，这一趋势并未放缓。开年不足半月，整体创新药行业的BD交易高达14起，覆盖小核酸、ADC、双抗、炎症免疫小分子及 AI 制药等多个技术方向。2026年被普遍视为其关键拐点之年，全球医药圈频频传来利好消息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114174511a719ab7f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114174511a719ab7f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09995","06978","BK1161","BK1574","06938"],"gpt_icon":1},{"id":"2603693714","title":"瑞博生物-B01月14日遭主力抛售360.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603693714","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603693714?lang=zh_cn&edition=full","pubTime":"2026-01-14 16:15","pubTimestamp":1768378512,"startTime":"0","endTime":"0","summary":"01月14日, 瑞博生物-B股价跌5.87%，报收76.15元，成交金额8746.6万元，换手率0.68%，振幅10.20%，量比0.00。瑞博生物-B今日主力资金净流出360.7万元，上一交易日主力净流出678.6万元。该股近5个交易日上涨31.10%，主力资金累计净流出401.6万元；近20日主力资金累计净流出401.6万元，其中净流出天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114161541a4c252ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114161541a4c252ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938"],"gpt_icon":1},{"id":"2603682104","title":"中国生物制药12亿收购赫吉亚，中外大药企缘何“独宠”小核酸？","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682104","media":"21世纪经济报道","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603682104?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:29","pubTimestamp":1768310953,"startTime":"0","endTime":"0","summary":"1月13日，港股制药龙头中国生物制药宣布，将以12亿元人民币全资收购国内siRNA创新药企赫吉亚生物。中国生物制药此次收购赫吉亚生物，被市场视为一次精准的战略卡位。有券商医药行业分析师对21世纪经济报道记者指出，去年投资圣因生物后，中国生物制药此次以12亿元人民币全资收购赫吉亚生物，进一步巩固了其在小核酸赛道的布局。目前，全球小核酸药物市场正迎来高速发展期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113213156a4bf1795&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113213156a4bf1795&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","IE00BZ08YR35.GBP","BK1515","BK1191","BK1521","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","06938","01177","BK1589"],"gpt_icon":1},{"id":"2603744425","title":"【券商聚焦】东吴证券首予瑞博生物“买入”评级 指肝外递送技术的拓展大幅提升公司上限","url":"https://stock-news.laohu8.com/highlight/detail?id=2603744425","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603744425?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:12","pubTimestamp":1768273974,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券研报指出，瑞博生物成立于2007年，专注于siRNA新药研发，聚焦多个患者众多的慢性疾病领域，是全球为数不多拥有自主知识产权的、且经过临床验证的GalNac递送技术的企业，其RiboGalSTAR TM技术平台已与勃林格殷格翰建立战略合作伙伴关系，有望获得最高23.6亿欧元的里程碑付款；肝外递送技术的拓展大幅提升了公司的天花板上限。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113122919a4bd1bb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113122919a4bd1bb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938"],"gpt_icon":1},{"id":"2603572106","title":"瑞博生物登陆港交所：高瓴创投六年耐心陪伴，再获一个百亿IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2603572106","media":"IPO早知道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603572106?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:56","pubTimestamp":1768272986,"startTime":"0","endTime":"0","summary":"高瓴在一个月之内收获的第六个IPO。作为“中国小核酸药物第一股”，瑞博生物自2007年成立至今已获得多家知名机构的投资。而按照瑞博生物C轮估值，目前高瓴已经获得超过5倍的投资回报。在商业化阶段，瑞博生物在高瓴创投的建议和配合下，先后与勃林格殷格翰、齐鲁制药达成两项战略合作，交易价值合计超过20亿美元。在瑞博生物案例中，高瓴创投自2020年投资后坚守六年，伴随企业穿越周期，最终迎来IPO时刻。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113130219953c852b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113130219953c852b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938"],"gpt_icon":1},{"id":"2603786555","title":"中金资本旗下基金直投项目——瑞博生物于港交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2603786555","media":"中金资本CICCca...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603786555?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:05","pubTimestamp":1768266307,"startTime":"0","endTime":"0","summary":"2026年1月9日，中国小核酸药物领军企业——苏州瑞博生物技术股份有限公司成功在香港联交所挂牌上市，当日收盘涨幅超41%，当日收盘市值约136亿港元。中金资本旗下基金于2020年参与瑞博生物C2轮融资，投资后推动“资本+投行”业务联动，中金公司担任本次上市的牵头保荐人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011309110097a1831f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011309110097a1831f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938"],"gpt_icon":1},{"id":"2602978085","title":"瑞博生物-B01月12日主力净流入637.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2602978085","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602978085?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:15","pubTimestamp":1768205725,"startTime":"0","endTime":"0","summary":"01月12日, 瑞博生物-B股价涨5.72%，报收86.80元，成交金额2.0亿元，换手率1.34%，振幅12.73%，量比0.00。该股近5个交易日上涨49.73%，主力资金累计净流入637.7万元；近20日主力资金累计净流入637.7万元，其中净流入天数为1日。该股主力净额占比0.04%，港股市场排名222/2717。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112162040a4b9b745&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112162040a4b9b745&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938"],"gpt_icon":0},{"id":"2602560110","title":"览富数据：H股IPO动态数据周报（2026第二期）","url":"https://stock-news.laohu8.com/highlight/detail?id=2602560110","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602560110?lang=zh_cn&edition=full","pubTime":"2026-01-12 12:00","pubTimestamp":1768190403,"startTime":"0","endTime":"0","summary":"2026年1月5日—2026年1月11日，精锋医疗-B、天数智芯、智谱、瑞博生物-B、金浔资源、MINIMAX-WP6家企业成功登陆港交所。2026年1月5日—2026年1月11日，按照港交所规定，LXJ International、星源材质2家企业未在递表后6个月内完成聆讯或上市，递表失效。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202601/12/20260112610363.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202601/12/20260112610363.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260112/31933623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1117","02513","03636","00100","09903","02675","06938","BK1128","HEXmain"],"gpt_icon":1},{"id":"2602321745","title":"农银国际作为整体协调人协助瑞博生物成功在香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2602321745","media":"农银国际","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602321745?lang=zh_cn&edition=full","pubTime":"2026-01-11 10:25","pubTimestamp":1768098352,"startTime":"0","endTime":"0","summary":"2026年1月9日，农银国际作为整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人协助苏州瑞博生物技术股份有限公司在香港交易所主板成功上市。瑞博生物此次发行价格为每H股57.97港元，募集资金约18亿港元。农银国际作为整体协调人，凭借自身对生物制药行业及跨境资本的深度理解，积极沟通高质量投资人，为公司成功上市保驾护航。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111104124a70c7475&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111104124a70c7475&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938"],"gpt_icon":1},{"id":"2602349599","title":"透视瑞博生物-B(06938)进阶之路：硬核技术壁垒 + 管线多元化，商业化前景可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2602349599","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602349599?lang=zh_cn&edition=full","pubTime":"2026-01-09 12:39","pubTimestamp":1767933562,"startTime":"0","endTime":"0","summary":"随着瑞博生物的这两款药物正式商业化，打开的成长空间亦十分具有想象力。这也为市场提供了充分依据，相信作为中国小核酸领域领跑者的瑞博生物，具备同样广阔的商业化前景。目前，瑞博生物正处在产品获批上市前的重要阶段。此次港股上市，是瑞博生物迈向全球领先小核酸药企的关键一步。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390801.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938"],"gpt_icon":0},{"id":"2602343602","title":"新年全省“第一股”花落苏州！","url":"https://stock-news.laohu8.com/highlight/detail?id=2602343602","media":"苏州新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602343602?lang=zh_cn&edition=full","pubTime":"2026-01-09 10:40","pubTimestamp":1767926433,"startTime":"0","endTime":"0","summary":"今天上午苏州瑞博生物技术股份有限公司成功在香港联合交易所主板挂牌上市成为今年全省首家上市企业此次上市，瑞博生物共计发行3161.04万股，发行价为每股57.97港元，募集资金总额超18亿港元。这也是苏州2026年登陆资本市场的第一股。据了解，伴随着瑞博生物在港交所的上市，苏州在港交所上市企业增至42家，同时也让港交所苏州生物医药行业企业进一步扩容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109104539a4ae52db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109104539a4ae52db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938"],"gpt_icon":0},{"id":"2602431706","title":"部分港股新股走强 瑞博生物-B涨近30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602431706","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602431706?lang=zh_cn&edition=full","pubTime":"2026-01-09 09:39","pubTimestamp":1767922758,"startTime":"0","endTime":"0","summary":"南方财经1月9日电，部分港股新股走强，截至发稿，瑞博生物-B(06938.HK)涨29.38%、金浔资源(03636.HK)涨26.67%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601093613813828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06938"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":-0.1258},{"period":"1month","weight":0.1868},{"period":"ytd","weight":0.1868}],"compareEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":0.0685},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.1175},{"period":"1year","weight":0.3541},{"period":"ytd","weight":0.0685}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州瑞博生物技术股份有限公司是一家主要从事小核酸药物研究和开发，尤其专注于小干扰核酸（siRNA）疗法的中国公司。该公司的主营业务是从事小核酸药物的创新，专注于心血管、代谢类、肾脏和肝病以及其他治疗领域。该公司的药物管线包括RBD4059、RBD5044、RBD7022、RBD7007、RBD2080、RBD1119、RBD1016等。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"瑞博生物-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞博生物-B,06938,瑞博生物-B股票,瑞博生物-B股票老虎,瑞博生物-B股票老虎国际,瑞博生物-B行情,瑞博生物-B股票行情,瑞博生物-B股价,瑞博生物-B股市,瑞博生物-B股票价格,瑞博生物-B股票交易,瑞博生物-B股票购买,瑞博生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}